Bexsero: A multicomponent vaccine for prevention of meningococcal disease

Andrew R. Gorringe*, Rolando Pajon

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

95 Citations (Scopus)


Serogroup B meningococcal (MenB) disease remains a serious public health problem for which a cross-protective vaccine effective against a wide range of MenB isolates has not been available. Novartis Vaccines has developed a vaccine for the prevention of MenB disease that contains four antigenic components: factor H binding protein (fHbp), neisserial adhesin A (NadA), Neisserial heparin binding antigen (NHBA) and outer membrane vesicles from a New Zealand epidemic strain (which provides PorA). This vaccine has been submitted for regulatory review in Europe so it is timely to review the design of the vaccine, results to date in clinical studies and the potential strain coverage provided by the vaccine. It is also critical to discuss the key issues for the long-term success of the vaccine which include strain coverage, potential persistence of protection, potential effects on carriage of MenB strains, potential for escape mutants and cost effectiveness.

Original languageEnglish
Pages (from-to)174-183
Number of pages10
JournalHuman Vaccines and Immunotherapeutics
Issue number2
Publication statusPublished - Feb 2012


  • NHBA
  • NadA
  • Neisseria meningitidis
  • PorA
  • Serogroup B
  • Vaccine
  • fHbp


Dive into the research topics of 'Bexsero: A multicomponent vaccine for prevention of meningococcal disease'. Together they form a unique fingerprint.

Cite this